Cover Image

Analysis of Deals in Neurodegenerative Diseases

Abstract

This new report follows the highly acclaimed and popular report series on key deal making therapy areas. It focuses on the five major neurodegenerative diseases:

  • Alzheimer' s disease
  • Parkinson' s disease
  • Multiple sclerosis
  • Epilepsy
  • Migraine

The report contains analysis of deals by deal and product type, number of deals year on year and the value and stage of development of these deals. It looks at the key players and includes case studies of the key deals being made within the five neurodegenerative diseases.

All deal data in this report are taken from the world-leading PharmaDealsR v2 Agreements database.

Table of Contents

1 Introduction to neurodegenerative diseases

  • 1.1 Overview
  • 1.2 Overall trends in neurodegenerative disease deals
    • 1.2.1 Comparison with other therapy areas
    • 1.2.2 Number of deals
    • 1.2.3 Value of deals
  • 1.3 Key players
  • 1.4 Deals by territory
  • 1.5 Impact of the ' credit crunch'
  • 1.6 Royalties

2 Alzheimer' s disease

  • 2.1 Overview
    • 2.1.1 Epidemiology
    • 2.1.2 Market size
    • 2.1.3 Current therapies
    • 2.1.4 Future treatments - products in development
  • 2.2 Trends in deal making in Alzheimer' s disease
    • 2.2.1 Overview
    • 2.2.2 Analysis of deals by deal type
    • 2.2.3 Deals by stage of development
    • 2.2.4 Deals by product type
    • 2.2.5 Key players

3 Parkinson' s Disease

  • 3.1 Overview
    • 3.1.1 Epidemiology
    • 3.1.2 Market size and trends
    • 3.1.3 Current therapies
    • 3.1.4 Future treatments - products in development
  • 3.2 Trends in deal making in Parkinson' s disease
    • 3.2.1 Analysis of deals by deal type
    • 3.2.2 Deals by stage of development
    • 3.2.3 Deals by product type
    • 3.2.4 Key players

4 Multiple sclerosis

  • 4.1 Overview
    • 4.1.1 Epidemiology
    • 4.1.2 Market size and trends
    • 4.1.3 Current therapies
    • 4.1.4 Future treatments - products in development
  • 4.2 Trends in deal making in Multiple sclerosis
    • 4.2.1 Analysis of deals by deal type
    • 4.2.2 Deals by stage of development
    • 4.2.3 Deals by product type
    • 4.2.4 Key players

5 Epilepsy

  • 5.1 Overview
    • 5.1.1 Epidemiology
    • 4.1.2 Market size and trends
    • 4.1.3 Current therapies
    • 5.1.4 Future treatments - products in development
  • 5.2 Trends in deal making in Epilepsy
    • 5.2.1 Analysis of deals by deal type
    • 5.2.2 Deals by stage of development
    • 5.2.3 Key players

6 Migraine

  • 6.1 Overview
    • 6.1.1 Epidemiology
    • 6.1.2 Market size and trends
    • 6.1.3 Current therapies
    • 6.1.4 Future treatments - products in development
  • 6.2 Trends in deal making in Migraine
    • 6.2.1 Analysis of deals by deal type
    • 6.2.2 Deals by stage of development
    • 6.2.3 Key players

7 Conclusions

8 Appendix 1: Alzheimer' s disease deals

  • 8.1 J&J and Elan
  • 8.2 TorreyPines and Eisai
  • 8.3 Medivation and Pfizer
  • 8.4 Myriad Genetics and Lundbeck
  • 8.5 CoMentis and Astellas
  • 8.6 Ablynx and Boehringer

9 Appendix 2: Parkinson' s Disease deals

  • 9.1 Newron Pharmaceuticals and Serono
  • 9.2 Biovail and Acadia

10 Appendix 3: Multiple sclerosis deals

  • 10.1 Facet Biotech and Abbott
  • 10.2 Bayer Schering and Genzyme
  • 10.3 BioMS Medical Corp and Eli Lilly
  • 10.4 Acorda Therapeutics and Biogen Idec
  • 10.5 Fast Forward LLC and Merck Serono

11 Appendix 4: Epilepsy deals

  • 11.1 Valeant and GSK
  • 11.2 BIAL Group and Separacor

12 Appendix 4: Migraine deals

  • 12.1 Pozen and GSK

Tables

  • 1 Prevalence rates for dementia by age group
  • 2 Main drugs currently marketed for AD
  • 3 Products in Phase III development for AD
  • 4 Selected AD deals
  • 5 AD drugs providing symptomatic relief
  • 6 Potentially disease-modifying AD agents
  • 7 Diagnostics
  • 8 Top AD dealmakers (1996 to 2009)
  • 9 Pfizer/Wyeth late stage AD pipeline
  • 10 Top AD principal/orginator organisations (1996 to 2009)
  • 11 Elan' s involvement in later stage AD drugs
  • 12 Products in Phase III development for PD
  • 13 Top PD dealmakers (1996 to 2009)
  • 14 Top PD principal/originator organisations (1996 to 2009)
  • 18 Biogen Idec' s MS pipeline portfolio
  • 19 Products in later stage development for epilepsy
  • 20 Top epilepsy dealmakers (1996 to 2009)
  • 21 Top epilepsy principal/originator organisations (1996 to 2009)
  • 22 Products in later stage development for migraine
  • 23 Top migraine dealmakers (1996 to 2009)

Figures

  • 1 Deal intensity by therapeutic area (1996 to 2009)
  • 2 Number of deals in five neurodegenerative disease areas (1996 to 2009)
  • 3 Value of deals in five neurodegenerative disease areas (1996 to 2009)
  • 3 Value of deals in five neurodegenerative disease areas (1996 to 2009)
  • 4 Number of deals by territory in five neurodegenerative disease areas (1996 to 2009)
  • 5 Impact of the credit crunch on deal-making
  • 6 Disclosed royalty rates for selected neurodegenerative diseases deals
  • 7 2009 worldwide sales of AD drugs (US$ M)
  • 8 total AD deals by deal type
  • 9 Year on year analysis by deal type
  • 10 Deal type by value
  • 11 Number of AD deals by stage of development
  • 12 Average value of AD deals by stage of development
  • 13 Total PD deals by deal type
  • 14 Year on year analysis by deal type
  • 15 Deal type by value
  • 16 Number of PD deals by stage of development
  • 17 Average value of PD deals by stage of development
  • 18 2009 worldwide sales of MS drugs (IUS$M)
  • 19 Total MS deals by deal type
  • 20 Year on year analysis by deal type
  • 21 Deal type by value
  • 22 Number of MS deals by stage of development
  • 23 Average value of MS deals by stage of development
  • 24 Total epilepsy deals by deal type
  • 25 Deal type by value
  • 26 Number of epilepsy deals by stage of development
  • 27 Total migraine deals by deal type
  • 28 Number of migraine deals by stage of development
  • 29 Average value of migraine deals by stage of development
Show More
Pricing
Get Notified
Email me when related reports are published